Should I buy or sell Agile Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AGRX shares. View AGRX analyst ratings or view top-rated stocks .

What is Agile Therapeutics' stock price target for 2024?

2 equities research analysts have issued 1-year target prices for Agile Therapeutics' stock. Their AGRX share price targets range from $5.00 to $12.00. On average, they expect the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 2,197.3% from the stock's current price. View analysts price targets for AGRX or view top-rated stocks among Wall Street analysts .

How have AGRX shares performed in 2024?

Agile Therapeutics' stock was trading at $1.95 at the beginning of 2024. Since then, AGRX shares have decreased by 81.0% and is now trading at $0.37. View the best growth stocks for 2024 here .

Are investors shorting Agile Therapeutics?

Agile Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 361,300 shares, an increase of 62.7% from the February 29th total of 222,100 shares. Based on an average trading volume of 698,200 shares, the days-to-cover ratio is currently 0.5 days. Approximately 12.7% of the company's shares are sold short. View Agile Therapeutics' Short Interest .

When is Agile Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our AGRX earnings forecast .

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics, Inc. (NASDAQ:AGRX) issued its earnings results on Tuesday, November, 2nd. The specialty pharmaceutical company reported ($7.20) earnings per share for the quarter, topping analysts' consensus estimates of ($7.60) by $0.40. The specialty pharmaceutical company had revenue of $1.29 million for the quarter, compared to analysts' expectations of $1.49 million. During the same quarter last year, the firm earned ($7.20) EPS.

When did Agile Therapeutics' stock split?

Agile Therapeutics's stock reverse split on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Agile Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Amarin (AMRN) , Inovio Pharmaceuticals (INO) , SCYNEXIS (SCYX) , Nabriva Therapeutics (NBRV) , AcelRx Pharmaceuticals (ACRX) , Micron Technology (MU) and Novavax (NVAX) .

How do I buy shares of Agile Therapeutics?

Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AGRX

Agile Therapeutics (AGRX) Stock Price, News & Analysis

→ I’m officially sounding the alarm. (From Altimetry) (Ad)

Free AGRX Stock Alerts

$0.37

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.37
▼
$0.38
50-Day Range: $0.27
▼
$1.22
52-Week Range: $0.20
▼
$7.00

Volume: 15,137 shs
Average Volume: 414,486 shs
Market Capitalization: $2.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.50

Get Agile Therapeutics alerts:

Agile Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 2,197.3% Upside
$8.50 Price Target
Short Interest: Bearish
12.68% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.59
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.28 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
Agile Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Agile Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
12.68% of the float of Agile Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Agile Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Agile Therapeutics has recently increased by 62.67%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Agile Therapeutics does not currently pay a dividend.
Dividend Growth
Agile Therapeutics does not have a long track record of dividend growth.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Agile Therapeutics has received a 56.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Estradiol medication" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Agile Therapeutics is -1.59.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Agile Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 7 people have searched for AGRX on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Agile Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Agile Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.50% of the stock of Agile Therapeutics is held by insiders.
Percentage Held by Institutions
Only 10.92% of the stock of Agile Therapeutics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Agile Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Agile Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

I’m officially sounding the alarm.

AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.

Just click here to watch my full uncensored interview.

About Agile Therapeutics Stock (NASDAQ:AGRX)

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.

AGRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AGRX Stock News Headlines

April 13, 2024 | americanbankingnews.com

Agile Therapeutics (NASDAQ:AGRX) versus Organogenesis (NASDAQ:ORGO) Head to Head Comparison

April 12, 2024 | americanbankingnews.com

Agile Therapeutics (NASDAQ:AGRX) Now Covered by Analysts at StockNews.com

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 1, 2024 | finance.yahoo.com

Agile Therapeutics, Inc. (NASDAQ:AGRX) Q4 2023 Earnings Call Transcript

March 30, 2024 | seekingalpha.com

Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript

March 29, 2024 | investorplace.com

AGRX Stock Earnings: Agile Therapeutics Misses EPS, Misses Revenue for Q4 2023

March 29, 2024 | finance.yahoo.com

Q4 2023 Agile Therapeutics Inc Earnings Call

March 28, 2024 | markets.businessinsider.com

Here's what to expect from Agile Therapeutics's earnings report

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

March 28, 2024 | finanznachrichten.de

Agile Therapeutics, Inc.: Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update

March 28, 2024 | globenewswire.com

Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update

March 26, 2024 | msn.com

Why Agile Therapeutics (AGRX) Stock Is Down 60%

March 26, 2024 | finanznachrichten.de

Agile Therapeutics, Inc.: Agile Therapeutics Announces Delisting from Nasdaq

March 25, 2024 | globenewswire.com

Agile Therapeutics Announces Delisting from Nasdaq

March 23, 2024 | benzinga.com

Latest News for Agile Therapeutics Stock (NASDAQ:AGRX)

March 21, 2024 | markets.businessinsider.com

Agile Therapeutics is about to announce its earnings — here's what to expect

March 21, 2024 | benzinga.com

Agile Therapeutics's Earnings: A Preview

March 21, 2024 | globenewswire.com

Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024

March 20, 2024 | globenewswire.com

Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024

March 13, 2024 | msn.com

Agile Therapeutics stock soars on complete debt payoff

March 13, 2024 | globenewswire.com

Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution

February 24, 2024 | investing.com

Agile Therapeutics reduces warrant exercise price

February 22, 2024 | benzinga.com

Agile Therapeutics Stock (NASDAQ:AGRX), Short Interest Report

February 22, 2024 | benzinga.com

What's Going On With Women Health Focused Agile Therapeutics Stock Today?

February 22, 2024 | finance.yahoo.com

Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds

February 22, 2024 | investorplace.com

Why Is Agile Therapeutics (AGRX) Stock Up 87% Today?

February 22, 2024 | globenewswire.com

Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds

See More Headlines

Receive AGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: NASDAQ:AGRX
CUSIP: N/A
CIK: 1261249
Web: www.agiletherapeutics.com
Phone: (609) 683-1880
Fax: N/A
Employees: 19
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.50
High Stock Price Target: $12.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +2,197.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($9.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,470,000.00
Net Margins: -73.83%
Pretax Margin: -73.83%
Return on Equity: N/A
Return on Assets: -179.07%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.46
Quick Ratio: 0.33

Sales & Book Value

Annual Sales: $19.59 million
Price / Sales: 0.13
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($5.51) per share
Price / Book: -0.07

Miscellaneous

Outstanding Shares: 6,860,000
Free Float: 6,822,000
Market Cap: $2.54 million
Optionable: Not Optionable
Beta: 1.42

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Alfred F. Altomari (Age 65)
Chairman, President & CEO
Comp: $644.4k
Mr. Geoffrey P. Gilmore (Age 58)
Senior VP & Chief Administrative Officer
Comp: $478.92k
Dr. Paul Korner M.B.A. (Age 58)
M.D., Senior VP & Chief Medical Officer
Comp: $480.4k
Mr. Scott M. Coiante (Age 57)
CFO, Senior VP & Treasurer
Comp: $520.45k
Matthew Riley
Head of Investor Relations & Corporate Communications
Mr. Robert G. Conway M.E. (Age 66)
Senior VP and Chief Corporate Planning & Supply Chain Officer
Comp: $444.11k
Ms. Amy Welsh (Age 53)
Senior VP & Chief Commercial Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

AGRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Agile Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AGRX shares.
View AGRX analyst ratings or view top-rated stocks.
What is Agile Therapeutics' stock price target for 2024?: 2 equities research analysts have issued 1-year target prices for Agile Therapeutics' stock. Their AGRX share price targets range from $5.00 to $12.00. On average, they expect the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 2,197.3% from the stock's current price.
View analysts price targets for AGRX or view top-rated stocks among Wall Street analysts.
How have AGRX shares performed in 2024?: Agile Therapeutics' stock was trading at $1.95 at the beginning of 2024. Since then, AGRX shares have decreased by 81.0% and is now trading at $0.37.
View the best growth stocks for 2024 here.
Are investors shorting Agile Therapeutics?: Agile Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 361,300 shares, an increase of 62.7% from the February 29th total of 222,100 shares. Based on an average trading volume of 698,200 shares, the days-to-cover ratio is currently 0.5 days. Approximately 12.7% of the company's shares are sold short.
View Agile Therapeutics' Short Interest.
When is Agile Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our AGRX earnings forecast.

How were Agile Therapeutics' earnings last quarter?: Agile Therapeutics, Inc. (NASDAQ:AGRX) issued its earnings results on Tuesday, November, 2nd. The specialty pharmaceutical company reported ($7.20) earnings per share for the quarter, topping analysts' consensus estimates of ($7.60) by $0.40. The specialty pharmaceutical company had revenue of $1.29 million for the quarter, compared to analysts' expectations of $1.49 million. During the same quarter last year, the firm earned ($7.20) EPS.
When did Agile Therapeutics' stock split?: Agile Therapeutics's stock reverse split on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What other stocks do shareholders of Agile Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).
How do I buy shares of Agile Therapeutics?: Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AGRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial